Antazoline HClCAS# 2508-72-7 |
2D Structure
- Cefditoren Pivoxil
Catalog No.:BCC4898
CAS No.:117467-28-4
- Cefoselis
Catalog No.:BCC4092
CAS No.:122841-10-5
- Balofloxacin
Catalog No.:BCC4892
CAS No.:127294-70-6
- Pefloxacin Mesylate Dihydrate
Catalog No.:BCC5089
CAS No.:149676-40-4
- Tinidazole
Catalog No.:BCC4866
CAS No.:19387-91-8
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 2508-72-7 | SDF | Download SDF |
PubChem ID | 17275 | Appearance | Powder |
Formula | C17H20ClN3 | M.Wt | 301.81 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 53 mg/mL (175.61 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 4,5-Dihydro-N-phenyl-N-(phenylmethy | ||
SMILES | [H+].[Cl-].C1CN=C(CN(Cc2ccccc2)c3ccccc3)N1 | ||
Standard InChIKey | SWKDMSRRIBZZAY-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H19N3.ClH/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16;/h1-10H,11-14H2,(H,18,19);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Imidazoline binding site ligand; a potent inducer of insulin secretion in rat pancreas. Also an antihistamine. |
Antazoline HCl Dilution Calculator
Antazoline HCl Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.3133 mL | 16.5667 mL | 33.1334 mL | 66.2669 mL | 82.8336 mL |
5 mM | 0.6627 mL | 3.3133 mL | 6.6267 mL | 13.2534 mL | 16.5667 mL |
10 mM | 0.3313 mL | 1.6567 mL | 3.3133 mL | 6.6267 mL | 8.2834 mL |
50 mM | 0.0663 mL | 0.3313 mL | 0.6627 mL | 1.3253 mL | 1.6567 mL |
100 mM | 0.0331 mL | 0.1657 mL | 0.3313 mL | 0.6627 mL | 0.8283 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Antazoline HCl is a first generation antihistamine, binding to the histamine H1 receptor and blocking the action of endogenous histamine.
- Salvisyrianone
Catalog No.:BCN4821
CAS No.:250691-57-7
- NNC 63-0532
Catalog No.:BCC7177
CAS No.:250685-44-0
- Pedunsaponin A
Catalog No.:BCN8192
CAS No.:250613-27-5
- Cyclo(RGDyK)
Catalog No.:BCC6512
CAS No.:250612-42-1
- (±)-Acetylcarnitine chloride
Catalog No.:BCC6617
CAS No.:2504-11-2
- Excavatin M
Catalog No.:BCN5116
CAS No.:250293-31-3
- PNU 177864 hydrochloride
Catalog No.:BCC7664
CAS No.:250266-51-4
- Boc-His(Dnp)-OH
Catalog No.:BCC3401
CAS No.:25024-53-7
- Otophylloside F
Catalog No.:BCN6441
CAS No.:250217-73-3
- 1,2:4,5-Di-O-isopropylidene-beta-D-fructopyranose
Catalog No.:BCN1475
CAS No.:25018-67-1
- Miriplatin hydrate
Catalog No.:BCC1751
CAS No.:250159-48-9
- Anamorelin
Catalog No.:BCC1362
CAS No.:249921-19-5
- FRATide
Catalog No.:BCC5821
CAS No.:251087-38-4
- Crebanine
Catalog No.:BCN5117
CAS No.:25127-29-1
- Urotensin II (human)
Catalog No.:BCC5796
CAS No.:251293-28-4
- SU 16f
Catalog No.:BCC7639
CAS No.:251356-45-3
- M344
Catalog No.:BCC2162
CAS No.:251456-60-7
- Tesaglitazar
Catalog No.:BCC7828
CAS No.:251565-85-2
- 5-Chloro-2-nitrobenzoic acid
Catalog No.:BCC8743
CAS No.:2516-95-2
- Acevaltrate
Catalog No.:BCN7127
CAS No.:25161-41-5
- Loline
Catalog No.:BCN2003
CAS No.:25161-91-5
- Isohomoarbutin
Catalog No.:BCN7612
CAS No.:25162-30-5
- Dynamin inhibitory peptide
Catalog No.:BCC1034
CAS No.:251634-21-6
- AM 1172
Catalog No.:BCC7675
CAS No.:251908-92-6
Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat.[Pubmed:7774667]
Eur J Pharmacol. 1995 Feb 24;275(1):91-8.
The relative potencies of imidazoline compounds to induce insulin secretion and vascular resistance were compared in the isolated perfused rat pancreas. On insulin secretion, only the two imidazolines, antazoline and efaroxan, induced a concentration-dependent response, antazoline being 10 times more potent than efaroxan. In contrast, idazoxan, a blocker of imidazoline I1 sites, at concentrations up to 30 microM, antagonized the insulin response to 10 microM efaroxan (IC50 approximately equal to 14 +/- 2 microM) without affecting that to 3 microM tolbutamide. On pancreatic vessels, not only antazoline and efaroxan but also idazoxan induced a concentration-dependent vasoconstriction; the rank order of agonist potency was antazoline > efaroxan > idazoxan. In addition, cimetidine, an imidazole known to bind imidazoline I1 sites, ineffective per se, partially reversed the insulin stimulatory effect of efaroxan without affecting its vasoconstrictor effect. This study demonstrates that the insulin secretory and vasoconstrictor actions of imidazolines involve different imidazoline sites in rat pancreas. The results provide evidence for an I1 type mediating insulin secretion on B cells and an I2 type mediating vasoconstriction in vessels.